WallStSmart

Abbott Laboratories (ABT)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 79% more annual revenue ($45.13B vs $25.27B). ABT leads profitability with a 13.9% profit margin vs 13.2%. ABT appears more attractively valued with a PEG of 1.33. SYK earns a higher WallStSmart Score of 57/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 5.3Quality: 4.8
Piotroski: 3/9

SYK

Buy

57

out of 100

Grade: C

Growth: 6.0Profit: 7.0Value: 4.7Quality: 6.0
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTFair Value (-0.1%)

Margin of Safety

-0.1%

Fair Value

$87.50

Current Price

$87.54

$0.04 premium

UndervaluedFair: $87.50Overvalued
SYKOvervalued (-9.7%)

Margin of Safety

-9.7%

Fair Value

$265.08

Current Price

$290.88

$25.80 premium

UndervaluedFair: $265.08Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$155.82B9/10

Large-cap with strong market position

Price/BookValuation
2.9x8/10

Reasonable price relative to book value

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$112.88B9/10

Large-cap with strong market position

Areas to Watch

ABT3 concerns · Avg: 3.0/10
P/E RatioValuation
25.1x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.33 suggests the stock is reasonably priced for its growth.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap. PEG of 1.40 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are P/E Ratio, Piotroski F-Score, EPS Growth.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

SYK carries more volatility with a beta of 0.93 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (57/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?